Previous Page
Researcher at Anasys Instruments, United States, and University of Illinois Urbana-Champaign, United States, present in ACS Nano a nanofabrication, chemical identification, and nanometer-scale chemical imaging of polymer nanostructures with better than 100nm spatial resolution. The new diagnostic tools that can support cutting-edge nanomanufacturing.
Jonathan R. Felts, Kevin Kjoller, Michael Lo, Craig B. Prater, and William P. King: Nanometer-Scale Infrared Spectroscopy of Heterogeneous Polymer Nanostructures Fabricated by Tip-Based Nanofabrication, In: ACS Nano, Volume 6, Issue 9, September 25, 2012, Pages 8015-8021, DOI:10.1021/nn302620f: http://dx.doi.org/10.1021/nn302620f
http://www.anasysinstruments.com/
B.E.S.S. Technologies (B.E.S.S.), and CNSE of the University at Albany (US) has entered into a licensing agreement with its first student spin-off company, which will allow B.E.S.S. to commercialize and begin scale-up of its innovative battery storage technology, enabling homegrown high-tech growth in upstate New York. B.E.S.S., which stands for Battery Energy Storage Systems, is a component design and engineering firm started by a group of CNSE graduate students in 2010. Working at CNSE’s Albany NanoTech Complex, B.E.S.S. developed an innovative process to build nanostructures which offer significantly increased energy storage capacity, faster charging rates, and a longer lifetime for lithium-ion batteries. CNSE has already assisted B.E.S.S. in obtaining more than $800,000 in funding through technology programs offered by the New York State Energy Research and Development Authority (NY- SERDA) and the National Science Foundation’s (NSF) Partnerships for Innovation program.
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins™, announced that the United States Patent and Trademark Office has recently issued five US patents to the company. The patents cover BIND- 014, the company’s lead Accurin product candidate for solid cancer tumors, and its Medicinal Nanoengineering™ platform which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites. The newly-issued patents include:
• US Patent 8,246,968 and US Patent 8,236,330: Both of these patents relate to BIND-014 and its targeting ligand.
• US 8,206,747 relates to the polymer composition of BIND-014 and US Patent 8,211,473 relates to a lyophilized composition of BIND-014. Both of these patents cover BIND-014 and BIND’s Medicinal Nanoengineering platform.
• US Patent 8,193,334 relates to BIND’s Medicinal Nanoengineering platform.